Zymar, Zymaxid Antitrust Direct Purchaser Class Action Settlement
Class Eligibility
All persons or entities in the United States who purchased branded Zymar or Zymaxid directly from any of the Defendants from and including June 15, 2010 through December 31, 2017.
Estimated Amount
Varies
Proof of Purchase
Yes
Case Name
Hartig v. Senju, et al.,Case No. 1:14-cv-00719,
District Court for the District of Delaware
Case Summary
The lawsuit alleges that Defendants engaged in an unlawful scheme to eliminate or delay generic competition for gatifloxacin ophthalmic solution (generic versions of their branded drugs Zymar and Zymaxid), a drug used to treat eye infections such as bacterial conjunctivitis, in violation of the Sherman Act. Defendants have denied any liability for these claims and have asserted various defenses to the claims.
Settlement Pool
$9,000,000
Settlement Website
Deadline
10/05/2018
